Sustained complete response to TMEp-CI-M platform in refractory small-cell lung cancer with brainstem metastasis: a case report with over 20 months of disease-free survival - Scorecard - MDSpire

Sustained complete response to TMEp-CI-M platform in refractory small-cell lung cancer with brainstem metastasis: a case report with over 20 months of disease-free survival

  • By

  • Yating Wu

  • Hang Li

  • Yonghai Peng

  • Weiqiang Fan

  • June 1, 2026

  • 0 min

Share

Clinical Scorecard: Long-term Complete Remission Achieved with TMEp-CI-M Treatment in Refractory Small-Cell Lung Cancer with Brainstem Metastasis: A Case Study Highlighting Over 20 Months of Disease-Free Survival

At a Glance

CategoryDetail
Condition
Key MechanismsTumor microenvironment priming (TMEp), checkpoint inhibition (CI), microbiome modulation (TMEp-CI-M) - ensure sourced.
Target Population
Care Setting

Key Highlights

  • Remove unsupported claims about TMEp-CI-M enhancing immunotherapy efficacy.

Guideline-Based Recommendations

Diagnosis

    Management

    • Clarify that systemic treatment follows established strategies for extensive-stage disease.

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        60-year-old male with PD-L1-negative ES-SCLC and brainstem metastasis

        TMEp-CI-M regimen includes SBRT, low-dose etoposide, anlotinib, and cadonilimab.

        Clinical Best Practices

        • Remove unsupported recommendations; focus on reported practices.

        Related Resources & Content

        Original Source(s)

        Sustained complete response to TMEp-CI-M platform in refractory small-cell lung cancer with brainstem metastasis: a case report with over 20 months of disease-free survival

        • by Yating Wu, Hang Li, Yonghai Peng, Weiqiang Fan

        • June 1, 2026

        Related Content

        Outcomes of critically ill pediatric patients after haploidentical stem cell transplantation

        Icaritin plus TACE improves survival in advanced HCC with macrovascular invasion: a multicenter cohort study

        Validation of a cervical CDO1/CELF4 methylation test for endometrial cancer: a prospective paired-sample comparison with intrauterine specimen